<![CDATA[<head>
<title>Pixantrone - demonstrates encouraging activity in non-Hodgkin's lymphoma</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="description" content="Pixantrone cancer drug treatment in CTI's development pipeline">
<meta name="description" content="Pixantrone cancer drug treatment in CTI's development pipeline">
<meta http-equiv="author" content="Cell Therapeutics, Inc.">
<meta name="description" content="Information on CTI's cancer treatment Pixantrone">
<meta name="Keywords" content="Pixantrone,lymphoma,NHL,leukemia,leukaemia,relapsed non-Hodgkin's lymphoma,myeloma,malignancies,clinical trials,chemotherapy,cancer therapies,cancer remission,Novuspharma,anthracycline,hematology,hemotology,haematology">
<meta content="document" name="resource-type">
<meta name="classification" content="BIO-BIOTECHNOLOGY">
<meta name="revisit-after" content="14 days">
<script language="JavaScript">
<!--
function MM_reloadPage(init) { //reloads the window if Nav4 resized
if (init==true) with (navigator) {if ((appName=="Netscape")&&(parseInt(appVersion)==4)) {
document.MM_pgW=innerWidth; document.MM_pgH=innerHeight; onresize=MM_reloadPage; }}
else if (innerWidth!=document.MM_pgW || innerHeight!=document.MM_pgH) location.reload();
}
MM_reloadPage(true);
// -->
</script>
</head>
<frameset rows="*,54" frameborder="NO" border="0" framespacing="0">
<frame src="prod_frame-iprod-pix.htm" frameborder="NO" marginwidth="0" marginheight="0" scrolling="AUTO" name="content">
<frame src="prod_nav-pipe.htm" scrolling="NO" noresize frameborder="NO" marginwidth="0" marginheight="0" name="navigation">
</frameset><noframes>]]><![CDATA[<head>
<title>Pixantrone - demonstrates encouraging activity in non-Hodgkin's lymphoma</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="description" content="Pixantrone cancer drug treatment in CTI's development pipeline">
<meta name="description" content="Pixantrone cancer drug treatment in CTI's development pipeline">
<meta http-equiv="author" content="Cell Therapeutics, Inc.">
<meta name="description" content="Information on CTI's cancer treatment Pixantrone">
<meta name="Keywords" content="Pixantrone,lymphoma,NHL,leukemia,leukaemia,relapsed non-Hodgkin's lymphoma,clinical trials,chemotherapy,cancer therapies,cancer remission,Novuspharma,anthracycline,hematology,haematology">
<meta content="document" name="resource-type">
<meta name="classification" content="BIO-BIOTECHNOLOGY">
<meta name="revisit-after" content="14 days">
<link rel='stylesheet' href='css/products.css' type='text/css'>
</head>
<body leftmargin="0" topmargin="0" marginwidth="0" marginheight="0" bgcolor="#6699cc" background="images/bg_prod.gif" onload="MM_preloadImages('images/prod_sidenav-cstud-on.gif','images/prod_sidenav-ppipe-on.gif','images/prod_sidenav-pgcpt-on.gif','images/prod_sidenav-tris-on.gif','images/prod_sidenav-pgtxl-on.gif')">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="bottom"><a href="default.htm" target="_parent"><img src="images/cti_logo-p.gif" width="65" height="80" alt="Cell Therapeutics making cancer more treatable" border="0"></a></td>
<td valign="bottom"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
<td valign="bottom" bgcolor="#80B1DB"><img src="images/cti_logo-title-p.gif" width="172" height="19" alt="Making Cancer More Treatable"></td>
<td><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
<td bgcolor="#80B1DB"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
<td valign="bottom" bgcolor="#80B1DB">
<table border="0" cellspacing="0" cellpadding="0" width="315">
<tr>
<td><a href="products.htm" target="_parent"><img src="images/prod_title-sm.gif" width="43" height="22" alt="Cancer research products in clinical trials" border="0"></a></td>
<td><img src="images/prod_title-div.gif" width="10" height="22" alt="/"></td>
<td><a href="prod_frame-ppipe.htm"><img src="images/prod_clinical_sm.gif" width="81" height="22" border="0" alt="ICancer research investigational product pipeline"></a></td>
<td><img src="images/prod_title-div.gif" width="10" height="22" alt="/"></td>
<td><img src="images/prod_title_pix.gif" width="191" height="22" alt="Pixantrone cancer research drug for non-Hodgkin's lymphoma"></td>
</tr>
</table>
</td>
<td bgcolor="#80B1DB"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
</tr>
<tr bgcolor="#FFFFFF">
<td width="65"><img src="images/0.gif" width="65" height="1" alt="" border="0"></td>
<td width="1"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
<td width="202"><img src="images/0.gif" width="202" height="1" alt="" border="0"></td>
<td width="1"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
<td width="50"><img src="images/0.gif" width="50" height="1" alt="" border="0"></td>
<td width="100%"><img src="images/0.gif" width="400" height="1" alt="" border="0"></td>
<td width="50"><img src="images/0.gif" width="50" height="1" alt="" border="0"></td>
</tr>
</table>
<table width="770" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="top">
<table width="270" border="0" cellspacing="0" cellpadding="0">
<tr>
<td height="128"><img src="images/0.gif" width="5" height="128" alt="" border="0"></td>
<td><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
<td><img src="images/prod_photo-2.jpg" width="202" height="130" alt="CTI cancer treatment drugs"></td>
<td><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
</tr>
<tr>
<td bgcolor="#FFFFFF"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
<td bgcolor="#FFFFFF"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
<td bgcolor="#FFFFFF"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
<td bgcolor="#FFFFFF"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
</tr>
<tr>
<td valign="TOP">
<table width="65" border="0" cellspacing="0" cellpadding="0">
<tr align="right">
<td><img src="images/0.gif" width="5" height="20" alt="" border="0"></td>
</tr>
<tr align="right">
<td><img src="images/0.gif" width="15" height="20" alt="" border="0"></td>
</tr>
<tr align="right">
<td><img src="images/prod_sidenav-arrow.gif" width="15" height="20" alt="" border="0"></td>
</tr>
<tr align="right">
<td><img src="images/0.gif" width="15" height="20" alt="" border="0"></td>
</tr>
<tr align="right">
<td><img src="images/0.gif" width="15" height="20" alt="" border="0"></td>
</tr>
<tr align="right">
<td><img src="images/0.gif" width="15" height="20" alt="" border="0"></td>
</tr>
<tr align="right">
<td><img src="images/0.gif" width="15" height="20" alt="" border="0"></td>
</tr>
<tr align="right">
<td><img src="images/0.gif" width="65" height="1" alt="" border="0"></td>
</tr>
</table>
</td>
<td><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
<td valign="TOP">
<table width="202" border="0" cellspacing="0" cellpadding="0">
<tr>
<td><img src="images/0.gif" width="5" height="20" alt="" border="0"></td>
</tr>
<tr>
<td><a href="products_pgtxl.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image1','','images/prod_sidenav-pgtxl-on.gif',1)" target="_parent"><img name="Image1" src="images/prod_sidenav-pgtxl.gif" width="123" height="20" border="0" alt="XYOTAX polyglutamate cancer research drug"></a></td>
</tr>
<tr>
<td><img name="Image2" border="0" src="images/prod_sidenav-pix-on.gif" width="123" height="20" alt="Pixantrone cancer research drug for non-Hodgkin's lymphoma"></td>
</tr>
<tr>
<td><a href="products_trisenox.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image3','','images/prod_sidenav-tris-on.gif',1)" target="_parent"><img name="Image3" src="images/prod_sidenav-tris.gif" width="123" height="20" alt="TRISENOX arsenic trioxide cancer research drug" border="0"></a></td>
</tr>
<tr>
<td><a href="products_pgcpt.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image4','','images/prod_sidenav-pgcpt-on.gif',1)" target="_parent"><img name="Image4" src="images/prod_sidenav-pgcpt.gif" width="123" height="20" border="0" alt="CT-2106 polyglutamate cancer research drug"></a></td>
</tr>
<tr>
<td><a href="products_cstudies.htm" onmouseout="MM_swapImgRestore()" onmouseover="MM_swapImage('Image5','','images/prod_sidenav-cstud-on.gif',1)" target="_parent"><img name="Image5" src="images/prod_sidenav-cstud.gif" width="123" height="20" border="0" alt="Clinical trials of CTI cancer research drugs"></a></td>
</tr>
</table>
</td>
<td><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
</tr>
<tr>
<td width="65"><img src="images/0.gif" width="65" height="1" alt="" border="0"></td>
<td width="1"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
<td width="202"><img src="images/0.gif" width="202" height="1" alt="" border="0"></td>
<td width="1"><img src="images/0.gif" width="1" height="1" alt="" border="0"></td>
</tr>
</table>
</td>
<td> </td>
<td valign="TOP" class="a">
<br>
<br>
<table width="400" border="0" cellspacing="0" cellpadding="0">
<tr>
<td valign="top" class="a">
<h2> Pixantrone</h2>
<p>We are developing pixantrone <em>(pick-san-troan) </em>for the treatment of non-Hodgkin's
lymphoma (NHL). Preclinical data and clinical studies
in more than 175 patients indicate that pixantrone
is easy to administer, may exhibit significantly lower
potential for cardiac toxicity, and may have more potent
anti-tumor activity than marketed anthracyclines.</p>
<p>Anthracyclines are one of the most potent classes of anti-cancer agents
used in front-line treatment of aggressive lymphoma,
leukemia, and breast cancer. For these diseases, anthracycline-containing
chemotherapy regimens can often produce long-term cancer
remissions. However, the currently marked anthracyclines
can cause severe, permanent, and life threatening cardiac
toxicity when administered beyond widely recognized
cumulative lifetime doses. </p>
<p>This toxicity prevents repeat
use of anthracyclines in the 70% of patients who
relapse after front-line anthracycline treatments.
In addition, the cardiac toxicity of anthracyclines
prevents their use in combination with other drugs
that also can cause cardiac toxicity. <br>
<br>
Pixantrone has been designed to reduce the potential
for these severe cardiotoxicities, which should
enable doctors to prescribe the drug to patients with recurring
cancer, or to patients with preexisting
cardiac risk factors. Pixantrone also is easier
to administer than traditional anthracyclines because it is non-toxic
to tissues and can
be administered intravenously, eliminating the
need for a central line. </p>
<h1>Pixantrone Clinical Trials</h1>
We are currently conducting several clinical trials with pixantrone
for NHL, including
a phase III pivotal
trial
in
third-line aggressive NHL in the U.S. and Europe. Pixantrone
has produced promising results to date, both as a single agent and
in combination with other agents used in the treatment of lymphoma.
See <a href="products_cstudies.htm" target="_parent">Clinical Trials</a>.
<br>
<h1>Tolerability and Efficacy of Pixantrone in Preclinical Studies</h1>
Preclinical studies show that pixantrone has a high level of activity
in blood-related tumors. In particular, pixantrone was curative in
some models of lymphoma and leukemia where currently marketed anthracyclines
and anthracycline-derivatives only prolonged survival. In these studies,
pixantrone demonstrated a high degree of efficacy at a third of its
maximum tolerated dose. In addition, significant synergy was observed
in combination with platinum.
<br>
<br>
Pixantrone also demonstrated tolerability advantages in these models and produced no relevant changes in heart tissues of animals who had not received previous anthracycline treatment. Pixantrone produced a slight dose dependent exacerbation of cardiac lesions in animals pre-treated with the current anthracyclines and anthracycline-derivatives.
<br>
<h1>Pixantrone<font size="1"></font> Resources</h1>
<table width="100%" border="0" cellpadding="0" cellspacing="2">
<tr valign="top">
<td width="3%">
•
</td>
<td width="97%"><a href="pdf/Pixantrone_fact-4pg.pdf">Pixantrone Fact
Sheet</a> (91k PDF) <br>
Read how pixantrone is targeted to: <br>
- Improved efficacy as a single agent in relapsed aggressive NHL <br>
- Reduced cardiotoxicity compared to standard anthracyclines <br>
- Ability to escalate the dose without the cumulative toxicities attributed to anthracyclines. </td>
</tr>
<tr valign="top">
<td width="3%">
•
</td>
<td width="97%"><a href="pdf/Pix_ref.pdf">Pixantrone References</a> (11k
PDF)
</td>
</tr>
</table>
<br>
<br>
<font size="1">Posted <font class="cr"> July 18, 2005</font></font><br>
<br>
<font class="cr">Copyright © 2004, 2005 Cell Therapeutics, Inc., Seattle, WA, USA. All rights reserved. "Making cancer more treatable" is a registered mark of CTI. </font>
<br> </td>
</tr>
</table>
</td>
<td><img src="images/0.gif" width="5" height="128" alt="" border="0"></td>
</tr>
<tr>
<td width="270"><img src="images/0.gif" width="270" height="1" alt="" border="0"></td>
<td width="50"><img src="images/0.gif" width="50" height="1" alt="" border="0"></td>
<td width="100%"><img src="images/0.gif" width="400" height="1" alt="" border="0"></td>
<td width="50"><img src="images/0.gif" width="50" height="1" alt="" border="0"></td>
</tr>
</table>
</body>]]>